

---

**From:** David Myers  
**To:** Michael Perfetto; Michael Dorsey; Michael Berryman; Thad Demos; Lisa Pehlke; Steve Cohen; Jinping McCormick; Rachelle Galant; Violet Wojtulewicz; Karen Stoedter  
**Sent:** 9/27/2011 4:01:36 PM  
**Subject:** Oxymorphone Promotion at McKesson

Team,

In support of your sales efforts, Actavis is currently running a two-part Oxymorphone marketing program with McKesson Drug Company. This campaign targets McKesson customers utilizing the following electronic and direct-contact methods:

- **Online** - a two-week advertising campaign on McKesson Connect, McKesson's exclusive online ordering and information portal that provides more than 30,000 unique daily log-ins with content and promotions to encourage sales. Our banner ad links to a sellsheet that has been customized with the McKesson ordering numbers and directly to McKesson's product ordering system.
- **Phone Awareness Campaign** - McKesson's team of dedicated generics specialists, GenericsConnect, will be contacting a targeted pool of 200 retail independent pharmacies with significant Opana ER brand sales beginning the week of September 26th. Each GenericsConnect Specialist has a regular series of ongoing conversations with the same customer base, and promotional awareness of Actavis' Oxymorphone is being incorporated into their outbound messaging during this campaign period.


We are continuing to search for unique opportunities to highlight and promote our Oxymorphone!

Best regards,

David

**David Myers**

*Senior Manager, Products & Communications*




Actavis

60 Columbia Rd. Bldg B # +1 973-993-4503 @ [DMYERS@actavis.com](mailto:DMYERS@actavis.com)  
Morristown, NJ 07960 United States # 973-993-4302 w [www.actavis.com](http://www.actavis.com)  
Internal VoIP number # 1254503

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way. Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

CONFIDENTIAL



ACTAVIS0622089

P-31278 \_ 00001

